Archives

Silver Dressings for the Healing of Venous Leg Ulcer a Meta-Analysis and Systematic Review

Abstract
This study was aimed to evaluate whether silver-containing dressings were superior to other types of dressings in the treatment of
venous leg ulcers (VLU) and their specific advantages.
Eight databases (Cochrane Library, PubMed, Web of Science, Ovid-Medline, Wanfang, VIP, China Biology Medicine, and China
National Knowledge Infrastructure) were systematically reviewed from inception to May 2019 for randomized controlled trials (RCTs).
The primary outcome was complete wound healing, and the secondary outcomes included absolute wound size changes (change of
cm2 area since baseline), relative changes (percentage change of area relative to baseline), and healing rate. Two reviewers
independently evaluated the risk of bias using the Cochrane Collaboration assessment tool and extracted the data according to the
predesigned table. All analyses were performed using the latest Review Manager Software (version 5.3).
A total of 8 studies qualified and were included in the meta-analysis, including 1057 patients (experiment: 526, control: 531). Both
complete wound healing and wound healing rates were reported in 5 studies. Two and 3 studies reported the effect of silver
dressings on absolute and relative wound size changes, respectively. Most of the studies used intention-to-treat analysis.
There was sufficient evidence that silver-containing dressings can accelerate the healing rate of chronic VLU and improve their
healing in a short duration of time. However, compared with other dressings, clinical trials with long-term follow-up data are needed to
confirm whether silver dressings have advantages regarding complete wound healing.
Abbreviations: CBM = China Biology Medicine, CI = confidence interval, CNKI = China National Knowledge Infrastructure,
PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis, Q test = Chi-Squared test, RCTs = randomized
controlled trials, RD = risk difference, SMD = standardized mean difference, VLU = venous leg ulcers, WMD = weighted mean
difference.
Keywords: silver dressings, venous leg ulcer, wound healing, meta-analysis

A Prospective Randomized Study The Usefulness and Efficacy of Negative Pressure Wound Therapy with Lipido-Colloid Polyester Mesh Compared to Traditional Negative Pressure Wound Therapy for Treatment of Pressure Ulcers

To improve healing of pressure ulcer wounds, it is important to optimize the conditions
of the area surrounding the wound. Negative pressure wound therapy (NPWT) promotes wound
healing, however, the removal of NPWT can cause pain or focal bleeding, delaying wound healing or
causing infection. In this study, we reviewed the e cacy of the lipidocolloid non-adherent dressing
(Urgotul®) as a wound contact layer. A total of 38 patients from the same facility who applied
NPWT from April 2016 to October 2019 were included and divided into two groups; NPWT with
the lipidocolloid non-adherent dressing (group 1, experimental group, 19 patients) and NPWT only
(group 2, control group, 19 patients). The condition of the wound was examined prior to NPWT
application, at one week, and again at three weeks after application. No significant di erences were
found between groups for general characteristics, bacterial culture or photo analysis. However,
when comparing groups based on the time of examination, there was a significant reduction of the
wound size in group 1 (p = 0.001) but not in group 2 (p = 0.082). Therefore, the current study finds
that using the lipidocolloid non-adherent dressing as a wound contact layer in NPWT stimulates
healing by shrinking the size of the pressure ulcer wound.

Clinical Evaluation of Technology Lipido-Colloid in the Management of Acute Wounds in China

Wound management has evolved from considering wound
dressings as a means to provide protection to a medium that enhances
wound healing and also takes into consideration patient aspects such as
atraumatic removal. Technology-lipido colloid (TLC) is described as a healing
matrix as it stimulates fibroblasts, which is achieved through maintaining a
moist wound environment. It also provides atraumatic removal, thus it not
only protects the wound but avoids unnecessary pain for the patients. This
article discusses five cases from China where the TLC was used on a variety
of wounds with positive outcomes both for the wound and the patients.

The Importance of Pain Reduction through Dressing Selection in Routine Wound Management The MAPP Study

Objective: To discover the incidence of pain in patients with acute or chronic wounds of various
causes during dressing removal, and the effect of switching to a non-adherent dressing.
l Method: A total of 656 primary care physicians reported the relevant details of all acute or chronic
wounds observed during routine visits throughout the study period. The pain experienced during
dressing changes was systematically evaluated. In patients with moderate to severe pain, a more
extensive evaluation was performed and they were invited to complete a self-evaluation questionnaire.
If the patients were seen at a subsequent visit, a new evaluation was performed.
l Results: In total 5850 patients were seen: 2914 with acute wounds and 2936 with chronic wounds.
During dressing changes, a similar number of patients with acute and chronic wounds reported
‘moderate to severe’ pain during the medical screening visit (79.9% and 79.7%) and ‘very severe’ pain in
their self-evaluation questionnaire completed at home (47% and 59% respectively). Dressing removal
was most painful when there was adherence to the wound bed. Switching to a new, non-adherent
dressing reduced pain during dressing changes in 88% of patients with chronic wounds and 95% of
patients with acute wounds.
l Conclusion: This study demonstrates that similar problems with patient acceptability arise
irrespective of wound aetiology. Pain is a major problem and is most often related to dressing selection.
Selecting a suitable, non-adherent dressing improves patient acceptability.

Evaluation of a Lipido-Colloid Wound Dressing in the Local Management of Leg Ulcers

Objective: To evaluate the efficacy, tolerance and acceptability of Urgotul and DuoDERM E dressings
in the local management of venous or mixed-aetiology leg ulcers.
l Method: This was a prospective multicentre randomised phase IV clinical trial conducted open-label
in parallel groups. It involved 20 investigating centres, including hospital dermatology and vascular
medicine departments, and private practices. Dermatologists and angiologists/phlebologists took part.
Subjects were adult, non-immunosuppressed patients presenting with a non-infected, non-malignant leg
ulcer of predominantly venous origin (ABPI >0.8). Ulcers were between 4cm2 and 40cm2 in size, with
granulation tissue covering more than 50% of their surface area. Ulcer duration ranged from three to
18 months. Patients were followed-up by the investigating physician for eight weeks on a weekly basis;
this included clinical examination, wound area tracings and photographs. Nurses (hospital or visiting)
assessed exudate volume and clinical appearance at dressing changes.
l Results: Ninety-one patients were included: 47 in the Urgotul group and 44 in the DuoDERM E
group. Baseline patient demographic data and wound characteristics were comparable in the two groups.
After eight weeks of treatment wound surface area had reduced by a mean of 61.3% in the Urgotul
group and 52.1% in the DuoDERM E group (NS); dressings were changed more frequently in the
DuoDERM E group (2.54 ± 0.57 times per week versus 2.31 ± 0.45 in the Urgotul group, p=0.047).
Thirty-three local adverse events were recorded in 27 patients: 10 in the Urgotul group and 23 in the
DuoDERM E group (p=0.039). Nurses reported better acceptability for the Urgotul dressing, based on
pain on removal, maceration and odour (p<0.0001).
l Conclusion: Both dressings showed similar efficacy for the local treatment of venous leg ulcers.
Nevertheless, medical and nursing staff reported better tolerance and acceptability for the
Urgotul dressing.

Using Urgotul Dressing for the Management of Epidermolysis Bullosa Skin Lesions

l Objective: To evaluate the acceptability, tolerance and efficacy of Urgotul wound dressing in the
management of epidermolysis bullosa (EB) skin lesions.
l Method: This was an open-label uncontrolled clinical trial involving 20 patients (11 adults and nine
children) with EB simplex or dystrophic EB. Patients were selected from the register of EB patients at
the investigating centre and included if they presented with at least one skin lesion requiring
management with a non-adherent wound dressing. Lesions were treated with the study dressing for a
maximum of four weeks. All dressing changes, wound parameters, pain and effect on quality of life were
recorded.
l Results: All patients completed the trial. Nineteen out of 20 wounds healed within 8.7 ± 8.5 days.
Overall, 11 patients (55%) considered that their quality of life had improved following use of the dressing,
which was also reported to be pain free and ‘very easy’ or ‘easy’ to remove at most dressing changes.
Nineteen out of 20 patients stated that they would use the study dressing to manage their lesions
in future.
l Conclusion: This study confirmed the very good acceptability and efficacy of Urgotul in the
treatment of skin lesions in patients with EB.

World Union of Wound Healing Societies Evidence in Wound Care

Wound management research improves patient care and clinical
outcomes by standardising assessment, planning and implementation
of treatment. In the field of wound care, high-level evidence is
possible, but it can be difficult to conduct due to the wide-ranging
nature of wounds and patients.
Additionally, there is an ever-growing variety of products and devices available to practitioners to improve healing rates and patient outcomes. In many cases, these products have enabled practitioners to heal more complex wounds and manage more
challenging and difficult cases. However, practitioners must be able to critically appraise evidence to make appropriate and effective evidence-based changes to practice.

A Prospective Study on the Efficacy of Sequential Treatment of Technology Lipido‐Colloid Impregnated with Silver and Technology Lipido‐Colloid Nano‐Oligosaccharide Factor in the Management of Venous Leg Ulcers

Background and Aims: Venous leg ulcers (VLUs) are associated with significant morbidity and poor quality of life (QOL). Compression therapy and wound dressing are the mainstay treatment options. Technology Lipido‐Colloid Impregnated with Silver (TLC‐Ag) reduces bacterial load and Technology Lipido‐Colloid Nano‐Oligosaccharide Factor (TLC‐NOSF) reduces elevated matrix metalloproteinases and improve wound healing. However, evidence is scarce on the role of sequential therapy. This study aims to evaluate if sequential treatment with TLC‐Ag and TLC‐ NOSF improves VLU wound healing and QOL.
Methods: This is a prospective cohort study from May 2020 to October 2021 on patients with VLUs who received sequential therapy, consisting of 2 weeks of TLC‐Ag followed by two‐layer compression bandage (2LB) with TLC‐NOSF until complete wound healing. Participants were followed‐up with weekly dressing changes. Our primary outcomes were wound area reduction (WAR) and Pressure Ulcer Scale of Healing (PUSH) score. Our secondary outcomes were QOL measures.
Results: There were 28 patients with 57.1% males (n = 16) with a mean age of 65.3 years. Mean duration of VLU was 13.9 ± 11.7 weeks before the initiation ofsequential therapy. Mean baseline wound area was 8.44 cm2
. Median time to wound healing was 10 weeks. 57.1% of patients achieved complete wound closure at3 months. There was significant WAR after 1 month (mean area 8.44–5.81 cm2 , 31.2% decrease) and after 3 months (mean area 8.44–2.53 cm2 , 70.0% decrease). Mean monthly WAR was 28.9%. PUSH score also decreased at 1 month (16.5% decrease, p < 0.001) and 3 months (63.3% decrease, p < .001) marks following the sequential therapy. EuroQol Visual Analog Scale (EQ‐VAS) improved following sequential therapy
(baseline: 69.0 ± 15.0, week 13: 80.2 ± 13.2, p < 0.001).
Conclusion: Sequential therapy with TLC‐Ag followed by TLC‐NOSF and 2LB is feasible, with good wound healing and improvement in QOL of patients with VLUs.

Application Tips – [Application Tips] UrgoStart Contact Layer

Welcome to this step by step guide on how to use UrgoStart Contact layer dressings.

All UrgoStart dressings are the only dressings clinically proven to reduce the healing time of wounds, thanks to the unique TLC-NOSF healing matrix.

All UrgoStart dressings are indicated for leg ulcers, diabetic foot ulcers, pressure ulcers and wounds that are at the risk of delayed healing.

UrgoStart contact layer dressings are pain-free at removal so you won’t cause unnecessary pain to your patients during dressing changes.

How to apply UrgoStart contact layer dressings:
• Cleanse the wound as per local protocol. Dry the surrounding skin carefully.
• Apply UrgoStart contact layer directly to the wound
• UrgoStart contact layer can be combined with a secondary dressing, suitable for the location and level of exudate, and secure it in place
• Apply the compression bandage system when prescribed (for mixed or venous leg ulcers)
• UrgoStart contact layer may be left in place up to 7 days, however change the dressing as advised by your healthcare professional.